C-JWVPImmunis
stem cell-derived secretome, multi-active biologics, regenerative factors
modulatingbiologic
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-JWVP
C-JWVPC-JWVPstem cell-derived secretome, multi-active biologics, regenerative factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immunis presents the view that age-acquired immune deficiency and age- or disease-related muscle atrophy are treatable conditions, and that stem cell-derived, natural-product immune therapies can be used to address age- and disease-related immune decline. The company frames its platform around secretomes and stem cell culture as the basis for these interventions.
SourceThe company presents aging as, in part, a loss or imbalance of beneficial secreted cellular factors that weakens immune regulation and contributes to age-related disease, especially muscle atrophy. Its stated belief is that stem cell-derived secretomes can replenish those missing signals, modulate immune responses, support tissue remodeling and regeneration, and therefore change the course of immune-related diseases and aging.
SourceImmunis states that age-acquired immune deficiency and age- or disease-related muscle atrophy can be targeted with stem cell-derived therapies. The company presents its STEM platform as an immune therapy based on secretomes and says its product uses stem cell culture to deliver natural, human immune modulators intended to address immune decline associated with aging and disease.
SourceImmunis заявляет, что возрастные иммунные дефициты и атрофия мышц, связанная с возрастом или заболеванием, могут быть устранены с помощью терапий на основе секретома. Компания представляет свой исследуемый продукт IMMUNA как натуральный человеческий иммуномодулирующий секретом, предназначенный для противодействия снижению иммунной функции и улучшения продолжительности здоровой жизни, что отражает убеждение, что восстановление нарушенной с возрастом иммунной сигнализации может изменить исходы при возраст-ассоциированных нарушениях.
Source